Finanzen von Novavax Inc (NVAX)NVAXNovavax Inc

Novavax, Inc. (NVAX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Licensing Royalties And Other, accounting for 66.7% of total sales, equivalent to $37.84M. Another important revenue stream is Product. Understanding this composition is critical for investors evaluating how NVAX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Novavax, Inc. maintains a gross margin of 78.93%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -85.55%, while the net margin is -94.16%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NVAX converts its operational activities into shareholder value.

In the context of the broader market, NVAX competes directly with industry leaders such as XERS and TRAX. With a market capitalization of $1.67B, it holds a leading position in the sector. When comparing efficiency, NVAX's gross margin of 78.93% stands against XERS's 83.47% and TRAX's N/A. Such benchmarking helps identify whether Novavax, Inc. is trading at a premium or discount relative to its financial performance.

Novavax has experienced fluctuating revenue, with a significant drop to $57 million in Q2 2026, down 76% year-over-year. However, it reported a gross margin of 78.93% in the same quarter, indicating strong profitability on sales despite overall revenue decline.